This free slidepack showcases the main points from Datamonitor Healthcare's HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access report. To view the full contents of the report in addition to the slides, log in to your Datamonitor Healthcare account or contact us for access.

Despite a high level of concern regarding spend on breast cancer medicines, access restrictions remain only mild to moderate. Spend in the indication is in the top three in oncology due to both medicines’ cost and high disease prevalence; however, most payers have not implemented access restrictions.

Outline:

• Market Context
• Methodology
• Global Access Levers
• Evidence and Value
• Access to Recently Approved and Pipeline Products
• Access Trends by Country
  
  • US
  • France
  • Germany
  • Italy
  • Spain
  • UK